European Movers: Valneva (VLA FP) +5.5%, Maersk (MAERSKB DC) +1.5%, Aviva (AV/ LN) +0.6%, Stellantis (STLAM IM/STLAP FP) U/C, Valmet (VALMT FH) -0.2%

A mixed movers wrap of this kind bundles idiosyncratic catalysts rather than a common macro thread, and the tape has historically treated each on its own mechanism rather than reading across. The regulatory item is the classic binary-path case: acceptance of a marketing application for review is a procedural milestone, not an approval, and in past episodes of this kind the initial pop in small-cap pharma names has tended to fade unless followed by a favourable assessment outcome, since validation starts the clock rather than settles the question. The rating changes sit in the usual pattern where single-bank moves from Sell to Hold or Buy to Hold shift a name only modestly unless they signal a broader sell-side turn, the tell being whether peer houses follow in subsequent sessions. The insurer's beat with reaffirmed multi-year targets fits the established sequence in that sector, where confirmation of capital-return or cost targets has mattered more to holders than the half-year print itself. The trade-remonstrance item is the one with the longer fuse: manufacturers contesting rules-of-origin or tariff treatment have historically pursued lobbying and formal comment channels over extended periods, and the market has tended to price the issue only as concrete cost estimates or final rule text emerge. Worth noting is that an unchanged print in a flagged name often reflects a story already in the price rather than an absence of news.